is it safe to invest in gthx?

**Investing in G1 Therapeutics (GTHX) carries some risk**, but there are also potential rewards, depending on your investment horizon and risk tolerance: 1. **Financial Performance**: GTHX reported a net loss of $10.22 million and a negative net margin of 36.40% for the latest quarter. This indicates that the company is currently unprofitable, which is a risk for investors. |Ticker|Name|Percentage Change|Date|code|market_code| |---|---|---|---|---|---| |GTHX.O|G1 Therapeutics|7.594936708860755|20240807|GTHX|185| 2. **Revenue Growth**: The company has shown a revenue growth rate of 11.82% year-on-year, which is a positive sign. However, this growth is not sufficient to cover the significant net loss. 3. **R&D Expenses**: GTHX has been investing heavily in research and development, with $7.32 million spent on R&D expenses in the latest quarter. This indicates a commitment to innovation, which could lead to future growth. 4. **Free Cash Flow**: The company has a positive free cash flow of $48.93 million, which is a good indicator of its liquidity and ability to fund operations. |Ticker|Name|Free Cash Flow|Date|code|market_code| |---|---|---|---|---|---| |GTHX.O|G1 Therapeutics|1.7018E7|2022 Q2|GTHX|185| |GTHX.O|G1 Therapeutics|-1.9276463925E7|2022 Q3|GTHX|185| |GTHX.O|G1 Therapeutics|-6.3465119625E7|2022 Q4|GTHX|185| |GTHX.O|G1 Therapeutics|2.8529E7|2023 Q1|GTHX|185| |GTHX.O|G1 Therapeutics|2.0311410145E7|2023 Q2|GTHX|185| |GTHX.O|G1 Therapeutics|-1313172.418|2023 Q3|GTHX|185| |GTHX.O|G1 Therapeutics|2.0789380563E7|2023 Q4|GTHX|185| |GTHX.O|G1 Therapeutics|4.8927E7|2024 Q1|GTHX|185| 5. **Stock Price and Analyst Ratings**: Despite the negative financials, the stock price has increased to $4.25, and analysts have a strong buy consensus with an average price target of $9. This suggests that analysts believe in the company's potential. |Ticker|Name|Closing Price|Date|code|market_code| |---|---|---|---|---|---| |GTHX.O|G1 Therapeutics|4.25|20240807|GTHX|185| 6. **Strategic Developments**: GTHX has several ongoing clinical trials and has licensed products that could lead to future revenue streams. The company's focus on oncology treatments is a promising area with significant unmet needs. 7. **Market Conditions**: The pharmaceutical industry can be volatile, and GTHX's stock has experienced significant fluctuations. Investors should consider their risk tolerance and investment horizon when deciding whether GTHX is a safe investment. In conclusion, while GTHX has potential for growth based on its R&D investments and strategic developments, the company's current lack of profitability and negative net margin present a risk. Investors should carefully consider these factors and consult with a financial advisor before making any investment decisions.